Protocol Title: A Phase 3 , Multicenter, Randomized, Double -Blind, Placebo -
Controlled Study to Assess the Efficacy and Safety of REL -1017 Monotherapy 
for Major Depressive Disorder  
(The RELIANCE -III Study)  
Protocol Number: REL -1017-[ADDRESS_1019921] Number  [STUDY_ID_REMOVED] 
Name [CONTACT_791]:  REL -1017  
Phase of Development:  3 
Indication: Major Depressive Disorder  
Sponsor: Relmada Therapeutics  Inc. 
Protocol Date:  August [ADDRESS_1019922] either personally 
identifiable  information or company confidential information. 
This may include, but is not limited to, redaction of the following: 
•Names, addresses, and other personally identifiable information
•Proprietary information, such as scales or coding systems, which are considered  
confidential  information.
•Other information as needed to protect the trade secret and/or confidential information of  
Relmada T herapeutics

INVESTIGATOR SIGNATURE [CONTACT_44561]:  A Phase 3, Multicenter, Randomized, Double -Blind, Placebo -Controlled 
Study to Assess the Efficacy and Safety of REL -1017 Monotherapy for 
Major Depressive Disorder  (The RELIANCE -III Study) 
 
Protocol Number:  REL -1017 -303 
Confidentiality  and Current Good Clinical Practice ( GCP )/E6(R2): 
I agree, as an Investigator conducting this study: 
•  
  
 
 
  
 
 
 
 
  
 
 
 
  
 
  
 
 
  
 
 
 
 
  

 
 
  
 
 
  
 
  
 
 
   
Name   [CONTACT_745654] (DD -Mmm -YYYY)  
 
   
Institution    
 
